<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01027195</url>
  </required_header>
  <id_info>
    <org_study_id>06-615</org_study_id>
    <nct_id>NCT01027195</nct_id>
    <nct_alias>NCT01448967</nct_alias>
  </id_info>
  <brief_title>Evaluation of the Efficacy of the Bipolar Sealer Aquamantys 6.0 in Patients Undergoing Total Hip Arthroplasty</brief_title>
  <acronym>Hip</acronym>
  <official_title>Evaluation of the Efficacy of the Bipolar Sealer Aquamantys 6.0 in Patients Undergoing Total Hip Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Salient Surgical Technologies</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present prospective, single-center, clinical trial is designed to evaluate the hemostatic
      efficacy of the hemostatic sealer Aquamantys 6.0™ in patients managed with total hip
      arthroplasty (THA). It is hypothesized that Aquamantys 6.0™ can improve hemostasis following
      total hip arthroplasty. Comparison of the functional and clinical results between THA
      patients having been exposed to Aquamantys 6.0™ versus a control group will be analyzed using
      several outcome measures including the Harris Hip Score and a pain scale. The primary
      variable of interest is transfusion requirements - specifically, number of patients managed
      with blood transfusion during the hospital stay after surgery. However, of secondary interest
      will be: 1) number of units transfused, 2) estimated intraoperative total blood loss, 3)
      change in pre- and post-operative hemoglobin levels, 4) total narcotic usage during hospital
      stay, 5) length of stay, 6) functional and pain outcomes (Harris Hip Score and Pain Scale),
      and 7) adverse events.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Managed With Blood Transfusion</measure>
    <time_frame>daily during hospital stay (an expected average of 4 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Units Transfused</measure>
    <time_frame>daily during hospital stay (an expected average of 4 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Blood Loss</measure>
    <time_frame>Intraoperative (day of surgery)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hemoglobin Level</measure>
    <time_frame>within 30 days before surgery (preop), day of hospital discharge</time_frame>
    <description>Change in hemoglobin level from baseline to the day of hospital discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Narcotic Usage (Morphine-equivalent mg) During Hospital Stay</measure>
    <time_frame>daily during hospital stay (an expected average of 4 days)</time_frame>
    <description>Sum of daily morphine-equivalent mg narcotic usage during hospital stay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay</measure>
    <time_frame>day of hospital discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Harris Hip Score (Outcome Score)</measure>
    <time_frame>within 30 days before surgery (preop), 4 weeks after surgery, 12 weeks after surgery</time_frame>
    <description>A scoring system used to evaluate the outcome after total hip replacement. Domains include pain (44 points), function (47 points), deformity (4 points), and range of motion (5 points). A total score is computed by summing the individual domain scores, with a maximum of 100 points. Higher values represent better outcomes. A total Harris Hip Score below 70 points is generally considered a poor result, 70 to 80 fair, 80 to 90 good, and 90 to 100 excellent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Score Scale</measure>
    <time_frame>within 30 days before surgery (preop), 4 weeks after surgery, 12 weeks after surgery</time_frame>
    <description>A single scoring system used to evaluate overall pain on a scale of integers 0 to 10, with 0 representing &quot;no pain&quot; and 10 representing &quot;unbearable pain.&quot; Thus, in this context, lower values represent better outcomes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Hip Arthritis</condition>
  <arm_group>
    <arm_group_label>Standard Bovie Electrocautery</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard Bovie electrocautery [Valleylab, Boulder, Colorado] used on surgical site during primary total hip arthroplasty to deliver high frequency electrical current to seal tissues and blood vessels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bipolar Radiofrequency</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aquamantys 6.0 bipolar sealer [Salient Surgical Technologies, Portsmouth, New Hampshire] used on surgical site during primary total hip arthroplasty to deliver radiofrequency energy coupled with saline solution irrigation for hemostatic sealing (i.e. shrinking of collagen in the walls of tissue vessels) at lower temperatures (&lt;100 degrees Celsius) than standard Bovie electrocautery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bipolar Radiofrequency (Aquamantys 6.0)</intervention_name>
    <arm_group_label>Bipolar Radiofrequency</arm_group_label>
    <other_name>Aquamantys 6.0</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard Bovie Electrocautery</intervention_name>
    <arm_group_label>Standard Bovie Electrocautery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18 - 85 years

          -  Sex: Both male and female will be included. The male-to-female ratio will depend upon
             the patient population.

          -  Stable Health: At the time of surgery based on physical examination and medical
             history.

          -  Patient exhibited preoperative radiographic evidence of joint degeneration consistent
             with THA that could not have been treated in non-operative fashion.

          -  Patient had severe hip pain and disability due to degenerative joint disease.

          -  Patient or patient's legal representative has signed the Informed Consent form. The
             patient is capable of making informed decisions regarding his/her healthcare.

        Exclusion Criteria:

          -  Patients with history of cardiac disease, liver disease or renal disease. Severe
             cardiac disease, liver disease and renal dysfunction can confound different parameters
             within this study. Patients with decreased cardiac function from prior myocardial
             infarction, cardiomyopathy or congestive heart failure will likely require
             transfusions with packed red blood cells at lower thresholds relative to healthy
             counterparts for cardioprotection. Therefore, patients with a prior history of
             myocardial infarction, cardiomyopathy, congestive heart failure or other significant
             cardiac history will be excluded from this study. In addition, patients with liver
             dysfunction from cirrhosis or hepatitis may have impaired production of factors in the
             clotting cascade which may make these individuals more prone to bleed, especially with
             the use of anticoagulants such as lovenox. For this reason, these patients will also
             be excluded from this study. Finally, individuals with renal dysfunction will have
             decreased creatinine clearance, which may artificially elevate the levels of lovenox,
             thereby promoting bleeding. In addition, individuals with severe renal disease may
             also have associated anemia which would complicate the transfusion threshold. For this
             reason, individuals with chronic renal failure, diabetic nephropathy, or decreased
             creatinine clearance will be excluded from this study.

          -  Patients predonating autologous blood.

          -  Patients with preoperative hemoglobin level less than 11.5 g/dL or a hematocrit less
             than 35%. Patients with a preoperative platelet count of less than 100,000.

          -  Patients undergoing bilateral or revision surgery.

          -  Evidence of bleeding or metabolic - based hemolytic disorder (hemophilia or
             anticoagulation use)

          -  Previous history of infection in the affected joint.

          -  Peripheral vascular disease.

          -  Patient was a poor compliance risk - treated for ethanol or drug abuse, physical or
             mental handicap, etc.

          -  Patients whose personal beliefs exclude the use of blood transfusions (example:
             Jehovah's witness).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wael K Barsoum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <results_reference>
    <citation>Barsoum WK, Klika AK, Murray TG, Higuera C, Lee HH, Krebs VE. Prospective randomized evaluation of the need for blood transfusion during primary total hip arthroplasty with use of a bipolar sealer. J Bone Joint Surg Am. 2011 Mar 16;93(6):513-8. doi: 10.2106/JBJS.J.00036.</citation>
    <PMID>21411700</PMID>
  </results_reference>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2009</study_first_submitted>
  <study_first_submitted_qc>December 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2009</study_first_posted>
  <results_first_submitted>August 29, 2012</results_first_submitted>
  <results_first_submitted_qc>October 30, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 29, 2012</results_first_posted>
  <last_update_submitted>October 30, 2012</last_update_submitted>
  <last_update_submitted_qc>October 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bipolar Radiofrequency</title>
          <description>Aquamantys 6.0 bipolar sealer [Salient Surgical Technologies, Portsmouth, New Hampshire] used on surgical site during primary total hip arthroplasty to deliver radiofrequency energy coupled with saline solution irrigation for hemostatic sealing (i.e. shrinking of collagen in the walls of tissue vessels) at lower temperatures (&lt;100 degrees Celsius) than standard Bovie electrocautery.</description>
        </group>
        <group group_id="P2">
          <title>Standard Bovie Electrocautery</title>
          <description>Standard Bovie electrocautery [Valleylab, Boulder, Colorado] used on surgical site during primary total hip arthroplasty to deliver high frequency electrical current to seal tissues and blood vessels.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bipolar Radiofrequency</title>
          <description>Aquamantys 6.0 bipolar sealer [Salient Surgical Technologies, Portsmouth, New Hampshire] used on surgical site during primary total hip arthroplasty to deliver radiofrequency energy coupled with saline solution irrigation for hemostatic sealing (i.e. shrinking of collagen in the walls of tissue vessels) at lower temperatures (&lt;100 degrees Celsius) than standard Bovie electrocautery.</description>
        </group>
        <group group_id="B2">
          <title>Standard Bovie Electrocautery</title>
          <description>Standard Bovie electrocautery [Valleylab, Boulder, Colorado] used on surgical site during primary total hip arthroplasty to deliver high frequency electrical current to seal tissues and blood vessels.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="71"/>
            <count group_id="B2" value="69"/>
            <count group_id="B3" value="140"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.4" spread="10.9"/>
                    <measurement group_id="B2" value="55.7" spread="11.0"/>
                    <measurement group_id="B3" value="55.5" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body-Mass Index</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Females</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.6" spread="7.1"/>
                    <measurement group_id="B2" value="29.2" spread="6.1"/>
                    <measurement group_id="B3" value="28.9" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Males</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.4" spread="4.7"/>
                    <measurement group_id="B2" value="30.4" spread="5.1"/>
                    <measurement group_id="B3" value="29.9" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Hemoglobin</title>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.6" spread="1.3"/>
                    <measurement group_id="B2" value="14.2" spread="1.2"/>
                    <measurement group_id="B3" value="14.4" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Number of Units Transfused</title>
        <time_frame>daily during hospital stay (an expected average of 4 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bipolar Radiofrequency</title>
            <description>Aquamantys 6.0 bipolar sealer [Salient Surgical Technologies, Portsmouth, New Hampshire] used on surgical site during primary total hip arthroplasty to deliver radiofrequency energy coupled with saline solution irrigation for hemostatic sealing (i.e. shrinking of collagen in the walls of tissue vessels) at lower temperatures (&lt;100 degrees Celsius) than standard Bovie electrocautery.</description>
          </group>
          <group group_id="O2">
            <title>Standard Bovie Electrocautery</title>
            <description>Standard Bovie electrocautery [Valleylab, Boulder, Colorado] used on surgical site during primary total hip arthroplasty to deliver high frequency electrical current to seal tissues and blood vessels.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Units Transfused</title>
          <units>units of blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="0.83"/>
                    <measurement group_id="O2" value="0.44" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Managed With Blood Transfusion</title>
        <time_frame>daily during hospital stay (an expected average of 4 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bipolar Radiofrequency</title>
            <description>Aquamantys 6.0 bipolar sealer [Salient Surgical Technologies, Portsmouth, New Hampshire] used on surgical site during primary total hip arthroplasty to deliver radiofrequency energy coupled with saline solution irrigation for hemostatic sealing (i.e. shrinking of collagen in the walls of tissue vessels) at lower temperatures (&lt;100 degrees Celsius) than standard Bovie electrocautery.</description>
          </group>
          <group group_id="O2">
            <title>Standard Bovie Electrocautery</title>
            <description>Standard Bovie electrocautery [Valleylab, Boulder, Colorado] used on surgical site during primary total hip arthroplasty to deliver high frequency electrical current to seal tissues and blood vessels.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Managed With Blood Transfusion</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Blood Loss</title>
        <time_frame>Intraoperative (day of surgery)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bipolar Radiofrequency</title>
            <description>Aquamantys 6.0 bipolar sealer [Salient Surgical Technologies, Portsmouth, New Hampshire] used on surgical site during primary total hip arthroplasty to deliver radiofrequency energy coupled with saline solution irrigation for hemostatic sealing (i.e. shrinking of collagen in the walls of tissue vessels) at lower temperatures (&lt;100 degrees Celsius) than standard Bovie electrocautery.</description>
          </group>
          <group group_id="O2">
            <title>Standard Bovie Electrocautery</title>
            <description>Standard Bovie electrocautery [Valleylab, Boulder, Colorado] used on surgical site during primary total hip arthroplasty to deliver high frequency electrical current to seal tissues and blood vessels.</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Blood Loss</title>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="315.2" spread="203.4"/>
                    <measurement group_id="O2" value="368.5" spread="277.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hemoglobin Level</title>
        <description>Change in hemoglobin level from baseline to the day of hospital discharge.</description>
        <time_frame>within 30 days before surgery (preop), day of hospital discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bipolar Radiofrequency</title>
            <description>Aquamantys 6.0 bipolar sealer [Salient Surgical Technologies, Portsmouth, New Hampshire] used on surgical site during primary total hip arthroplasty to deliver radiofrequency energy coupled with saline solution irrigation for hemostatic sealing (i.e. shrinking of collagen in the walls of tissue vessels) at lower temperatures (&lt;100 degrees Celsius) than standard Bovie electrocautery.</description>
          </group>
          <group group_id="O2">
            <title>Standard Bovie Electrocautery</title>
            <description>Standard Bovie electrocautery [Valleylab, Boulder, Colorado] used on surgical site during primary total hip arthroplasty to deliver high frequency electrical current to seal tissues and blood vessels.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin Level</title>
          <description>Change in hemoglobin level from baseline to the day of hospital discharge.</description>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="1.6"/>
                    <measurement group_id="O2" value="-5.3" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Narcotic Usage (Morphine-equivalent mg) During Hospital Stay</title>
        <description>Sum of daily morphine-equivalent mg narcotic usage during hospital stay.</description>
        <time_frame>daily during hospital stay (an expected average of 4 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bipolar Radiofrequency</title>
            <description>Aquamantys 6.0 bipolar sealer [Salient Surgical Technologies, Portsmouth, New Hampshire] used on surgical site during primary total hip arthroplasty to deliver radiofrequency energy coupled with saline solution irrigation for hemostatic sealing (i.e. shrinking of collagen in the walls of tissue vessels) at lower temperatures (&lt;100 degrees Celsius) than standard Bovie electrocautery.</description>
          </group>
          <group group_id="O2">
            <title>Standard Bovie Electrocautery</title>
            <description>Standard Bovie electrocautery [Valleylab, Boulder, Colorado] used on surgical site during primary total hip arthroplasty to deliver high frequency electrical current to seal tissues and blood vessels.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Narcotic Usage (Morphine-equivalent mg) During Hospital Stay</title>
          <description>Sum of daily morphine-equivalent mg narcotic usage during hospital stay.</description>
          <units>total morphine-equivalent mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156.1" spread="130.2"/>
                    <measurement group_id="O2" value="164.9" spread="123.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Stay</title>
        <time_frame>day of hospital discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bipolar Radiofrequency</title>
            <description>Aquamantys 6.0 bipolar sealer [Salient Surgical Technologies, Portsmouth, New Hampshire] used on surgical site during primary total hip arthroplasty to deliver radiofrequency energy coupled with saline solution irrigation for hemostatic sealing (i.e. shrinking of collagen in the walls of tissue vessels) at lower temperatures (&lt;100 degrees Celsius) than standard Bovie electrocautery.</description>
          </group>
          <group group_id="O2">
            <title>Standard Bovie Electrocautery</title>
            <description>Standard Bovie electrocautery [Valleylab, Boulder, Colorado] used on surgical site during primary total hip arthroplasty to deliver high frequency electrical current to seal tissues and blood vessels.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stay</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="1.1"/>
                    <measurement group_id="O2" value="3.4" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Harris Hip Score (Outcome Score)</title>
        <description>A scoring system used to evaluate the outcome after total hip replacement. Domains include pain (44 points), function (47 points), deformity (4 points), and range of motion (5 points). A total score is computed by summing the individual domain scores, with a maximum of 100 points. Higher values represent better outcomes. A total Harris Hip Score below 70 points is generally considered a poor result, 70 to 80 fair, 80 to 90 good, and 90 to 100 excellent.</description>
        <time_frame>within 30 days before surgery (preop), 4 weeks after surgery, 12 weeks after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bipolar Radiofrequency</title>
            <description>Aquamantys 6.0 bipolar sealer [Salient Surgical Technologies, Portsmouth, New Hampshire] used on surgical site during primary total hip arthroplasty to deliver radiofrequency energy coupled with saline solution irrigation for hemostatic sealing (i.e. shrinking of collagen in the walls of tissue vessels) at lower temperatures (&lt;100 degrees Celsius) than standard Bovie electrocautery.</description>
          </group>
          <group group_id="O2">
            <title>Standard Bovie Electrocautery</title>
            <description>Standard Bovie electrocautery [Valleylab, Boulder, Colorado] used on surgical site during primary total hip arthroplasty to deliver high frequency electrical current to seal tissues and blood vessels.</description>
          </group>
        </group_list>
        <measure>
          <title>Harris Hip Score (Outcome Score)</title>
          <description>A scoring system used to evaluate the outcome after total hip replacement. Domains include pain (44 points), function (47 points), deformity (4 points), and range of motion (5 points). A total score is computed by summing the individual domain scores, with a maximum of 100 points. Higher values represent better outcomes. A total Harris Hip Score below 70 points is generally considered a poor result, 70 to 80 fair, 80 to 90 good, and 90 to 100 excellent.</description>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Preoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.0" spread="12.2"/>
                    <measurement group_id="O2" value="60.4" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Weeks Postoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.4" spread="9.8"/>
                    <measurement group_id="O2" value="78.4" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Weeks Postoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.8" spread="8.2"/>
                    <measurement group_id="O2" value="95.1" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Score Scale</title>
        <description>A single scoring system used to evaluate overall pain on a scale of integers 0 to 10, with 0 representing &quot;no pain&quot; and 10 representing &quot;unbearable pain.&quot; Thus, in this context, lower values represent better outcomes.</description>
        <time_frame>within 30 days before surgery (preop), 4 weeks after surgery, 12 weeks after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bipolar Radiofrequency</title>
            <description>Aquamantys 6.0 bipolar sealer [Salient Surgical Technologies, Portsmouth, New Hampshire] used on surgical site during primary total hip arthroplasty to deliver radiofrequency energy coupled with saline solution irrigation for hemostatic sealing (i.e. shrinking of collagen in the walls of tissue vessels) at lower temperatures (&lt;100 degrees Celsius) than standard Bovie electrocautery.</description>
          </group>
          <group group_id="O2">
            <title>Standard Bovie Electrocautery</title>
            <description>Standard Bovie electrocautery [Valleylab, Boulder, Colorado] used on surgical site during primary total hip arthroplasty to deliver high frequency electrical current to seal tissues and blood vessels.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score Scale</title>
          <description>A single scoring system used to evaluate overall pain on a scale of integers 0 to 10, with 0 representing &quot;no pain&quot; and 10 representing &quot;unbearable pain.&quot; Thus, in this context, lower values represent better outcomes.</description>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Preoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="2.2"/>
                    <measurement group_id="O2" value="6.4" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Weeks Postoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.7"/>
                    <measurement group_id="O2" value="1.7" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Weeks Postoperative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="1.7"/>
                    <measurement group_id="O2" value="0.9" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bipolar Radiofrequency</title>
          <description>Aquamantys 6.0 bipolar sealer [Salient Surgical Technologies, Portsmouth, New Hampshire] used on surgical site during primary total hip arthroplasty to deliver radiofrequency energy coupled with saline solution irrigation for hemostatic sealing (i.e. shrinking of collagen in the walls of tissue vessels) at lower temperatures (&lt;100 degrees Celsius) than standard Bovie electrocautery.</description>
        </group>
        <group group_id="E2">
          <title>Standard Bovie Electrocautery</title>
          <description>Standard Bovie electrocautery [Valleylab, Boulder, Colorado] used on surgical site during primary total hip arthroplasty to deliver high frequency electrical current to seal tissues and blood vessels.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary Ischemic Event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Deep Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep-Vein Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Wael K Barsoum, MD</name_or_title>
      <organization>The Cleveland Clinic</organization>
      <phone>216-444-7515</phone>
      <email>barsouw@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

